These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17321668)

  • 21. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
    Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
    J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection.
    Mitterberger MJ; Aigner F; Horninger W; Ulmer H; Cavuto S; Halpern EJ; Frauscher F
    Eur Radiol; 2010 Dec; 20(12):2791-6. PubMed ID: 20571801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy.
    Colleselli D; Bektic J; Schaefer G; Frauscher F; Mitterberger M; Brunner A; Schwentner C; Bartsch G; Horninger W; Pelzer AE
    BJU Int; 2007 Dec; 100(6):1264-7. PubMed ID: 17850369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging.
    Robertson NL; Moore CM; Ambler G; Bott SR; Freeman A; Gambarota G; Jameson C; Mitra AV; Whitcher B; Winkler M; Kirkham A; Allen C; Emberton M
    Contemp Clin Trials; 2013 Jan; 34(1):80-9. PubMed ID: 23085153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
    Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
    J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate.
    Aigner F; Pallwein L; Mitterberger M; Pinggera GM; Mikuz G; Horninger W; Frauscher F
    BJU Int; 2009 Feb; 103(4):458-63. PubMed ID: 19021610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decision analysis of dutasteride use for patients with negative prostate biopsy.
    Vickers AJ; Sjoberg DD
    Urology; 2015 Feb; 85(2):337-41. PubMed ID: 25623680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of prostate biopsy in patients under the dutasteride treatment.
    Obinata D; Nakahara K; Yoshizawa T; Mochida J; Yamaguchi K; Takahashi S
    Medicine (Baltimore); 2022 Nov; 101(44):e31658. PubMed ID: 36343082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with Persistently Elevated PSA and Negative Results of TRUS-Biopsy: Does 6-Month Treatment with Dutasteride can Indicate Candidates for Re-Biopsy. What is the Best of Saturation Schemes: Transrectal or Transperineal Approach?
    Kravchick S; Lobik L; Cytron S; Kravchenko Y; Dor DB; Peled R
    Pathol Oncol Res; 2015 Sep; 21(4):985-9. PubMed ID: 25753982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
    Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
    J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
    Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
    J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
    Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
    J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.